State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Acta Pharmacol Sin. 2011 Aug;32(8):1019-24. doi: 10.1038/aps.2011.49. Epub 2011 Jul 18.
To examine the potential correlation between serum REST corepressor 3 (RCOR3) level and the outcome of patients with hepatitis B.
Concanavalin A (ConA)-induced mouse hepatitis model was used. The mRNA level of RCOR3 in mouse liver was measured using GeneChip array and real-time PCR. One hundred seventy-seven patients with hepatitis B and 34 healthy individuals were categorized into six groups including mild chronic hepatitis, moderate chronic hepatitis B, severe hepatitis B (SHB), cirrhosis, hepatocellular carcinoma (HCC) and healthy control. Serum levels of human RCOR3 were measured using ELISA.
In the mouse hepatitis model, the mRNA level of RCOR3 in liver was reduced early after exposure to ConA, then increased after 6 h of exposure. There was no significant difference in the serum RCOR3 level between the mild chronic hepatitis B and the control groups. The serum RCOR3 level was significantly increased in the moderate chronic hepatitis B group, but significantly reduced in SHB, cirrhosis and HCC groups, as compared with the control group. Moreover, the serum RCOR3 levels in SHB, cirrhosis and liver cancer patients were significantly lower than those in the patients with moderate chronic hepatitis B and with mild chronic hepatitis B. Rank correlation analysis revealed a significant correlation between serum RCOR3 level and total bilirubin (r=-0.305, P<0.01). There was no significant correlation between RCOR3 on one hand, and alanine transaminase (r=0.014, P>0.05) or aspartate transaminase (r=-0.079, P>0.05) on the other hand.
Serum RCOR3 level may reflect the degree of liver damage, which might be a potential biomarker for the outcome of patients with hepatitis B.
探讨血清 REST 核心抑制因子 3（RCOR3）水平与乙型肝炎患者预后的潜在相关性。
采用刀豆蛋白 A（ConA）诱导的小鼠肝炎模型。采用基因芯片和实时 PCR 检测小鼠肝组织中 RCOR3 的 mRNA 水平。将 177 例乙型肝炎患者和 34 名健康个体分为六组，包括轻度慢性乙型肝炎、中度慢性乙型肝炎、乙型肝炎重型（SHB）、肝硬化、肝癌（HCC）和健康对照组。采用 ELISA 检测人血清 RCOR3 水平。
在小鼠肝炎模型中，暴露于 ConA 后早期肝组织中 RCOR3 的 mRNA 水平降低，6 h 后升高。轻度慢性乙型肝炎组与对照组血清 RCOR3 水平无显著差异。中度慢性乙型肝炎组血清 RCOR3 水平显著升高，但 SHB、肝硬化和 HCC 组血清 RCOR3 水平显著降低，与对照组相比差异有统计学意义。此外，SHB、肝硬化和肝癌患者的血清 RCOR3 水平明显低于中度慢性乙型肝炎和轻度慢性乙型肝炎患者。秩相关分析显示，血清 RCOR3 水平与总胆红素呈显著负相关（r=-0.305，P<0.01）。RCOR3 与丙氨酸转氨酶（r=0.014，P>0.05）或天冬氨酸转氨酶（r=-0.079，P>0.05）无显著相关性。
血清 RCOR3 水平可能反映肝损伤程度，有望成为乙型肝炎患者预后的潜在生物标志物。
